Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs. Standard 28 Days, Enabling Patients To Achieve And Maintain Target Medication Levels More Quickly
Indivior數據顯示，快速啓動每月一次的SUBLOCADE可顯著提高阿片類藥物使用障礙患者的保留率，尤其是芬太尼陽性參與者的保留率；研究還在一週後進行了第二次SUBLOCADE注射，VS.標準 28 天，使患者能夠更快地達到和維持目標藥物水平
- Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.
- Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder.
- Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal injection site, were also presented at CSAM.
- SUBLOCADE has received Priority Review designation from the U.S. Food and Drug Administration (FDA) to expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose as well as inclusion of alternative injection sites.
- 數據顯示，快速啓動每月一次的SUBLOCADE可顯著提高阿片類藥物使用障礙（OUD）患者的保留率，尤其是芬太尼陽性參與者的保留率。與標準28天相比，該研究還在一週後進行了第二次SUBLOCADE注射，使患者能夠更快地達到和維持目標藥物水平。
- 這項研究在2024年加拿大成癮醫學學會（CSAM）會議上發表，強調了快速啓動有可能改變阿片類藥物使用障礙的治療方法。
- cSAM還公佈了支持在包括大腿、上臂和臀部在內的替代注射部位皮下注射SUBLOCADE與當前皮下腹部注射部位對比的數據。
- SUBLOCADE已獲得美國食品藥品監督管理局（FDA）的優先審查指定，將標籤範圍擴大到在單劑經粘膜丁丙諾啡一小時後快速啓動以及納入替代注射部位。
RICHMOND, Va., Nov. 19, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inject opioids or use fentanyl without increasing the risk of precipitated opioid withdrawal (POW) symptoms. The data were presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference in Hamilton, Ontario, Canada.
弗吉尼亞州里士滿，2024年11月19日 /PRNewswire/ — Indivior PLC（納斯達克/倫敦證券交易所股票代碼：INDV）上週分享了一項針對尋求治療的阿片類藥物依賴參與者的隨機開放標籤子研究的結果，該研究表明，與標準起始劑（SI）相比，使用SUBLOCADE（丁丙諾啡緩釋注射）快速啓動（RI）治療OUD可顯著提高治療保留率。NCT04995029一天內使用SUBLOCADE的RI可以減少治療障礙並提高患者保留率，尤其是那些經常注射阿片類藥物或使用芬太尼但不會增加急性阿片類藥物戒斷（POW）症狀風險的患者。這些數據是在加拿大安大略省漢密爾頓舉行的2024年加拿大成癮醫學學會（CSAM）會議上公佈的。
